Europe
Sanofi was formally charged over Depakine, its epilepsy drug, for not taking action when they first discovered the fetal risks when taken by pregnant women.
The BioNTech scientist said his vaccine can “bash the virus over the head”.
Synairgen announced today that its data from the SG016 trial was published in the journal The Lancet Respiratory Medicine. The trial, which included 101 hospitalized COVID-19 patients, looked at SNG001 as a potential treatment.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
This morning, the company announced it bolstered its own gene therapy activities with the acquisition of Handl Therapeutics BV, a rapidly growing and transformative gene therapy company.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
AstraZeneca reported that the CALAVI Phase II trials of Calquence (acalabrutinib) in hospitalized patients with respiratory symptoms of COVID-19 failed to meet the trials’ primary efficacy endpoint.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Days after Pfizer and BioNTech announced their mRNA vaccine for COVID-19 demonstrated 90% efficacy at an interim analysis, Russia is claiming the vaccine it authorized in the fight against the novel coronavirus is 92% effective following an interim analysis of its ongoing Phase III study.
Affimed receives $60 million up front with potential for up to $2 billion more in partnership deal with Roivant Sciences.
PRESS RELEASES